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Chlamydia trachomatis (CT) is the most commonly reported bacterial sexually transmitted infection (STI) in 29 
developed nations [1]. In 2015 the World Health Organisation (WHO) estimated the global prevalence of CT to 30 
be 4.2% among 15 to 49-year-old men and women [2]. CT is asymptomatic in over 80% of cases among women, 31 
and in about 10% of cases, it can lead to pelvic inflammatory disease (PID), which increases the risk of ectopic 32 
pregnancy or infertility [3-6].  33 
Spontaneous resolution of chlamydia has been described in the literature with reports of up to 44% of infections 34 
clearing between diagnosis and treatment [7-10]. However, the key limitation of these reports is that they all used 35 
DNA or rRNA based amplification tests to diagnose CT and these assays do not differentiate between viable and 36 
non-viable DNA. Given the sensitivity of NAAT assays and the fact that they do not require viable organism to 37 
diagnose an infection, it is possible that a percentage of these initial diagnoses represented non-viable DNA 38 
elements rather than viable infectious particles, thereby over-estimating spontaneous resolution.  39 
To overcome potential miss-classification bias, the detection of mRNA in addition to DNA could allow the 40 
differentiation between viable infection and non-viable DNA.  In this study, we modified a previously published 41 
CT mRNA detection (omp2) method from reverse transcriptase qPCR (RTqPCR) to digital PCR (dPCR), 42 
(allowing for direct quantification of the target molecule using microfluidic generated droplets and capillary flow 43 
fluorescence detection) [11] and aimed to evaluate it using a sample of CT DNA PCR positive women to 44 
differentiate between viable and non-viable DNA. Previous studies have shown that dPCR has better sensitivity 45 
with as much as a 50-fold improvement on current real time PCR assays and provides quantitative bacterial load 46 
data on every sample [12]. We then assessed dPCR for detection of chlamydial mRNA and DNA versus DNA 47 
detection alone.  48 
Methods 49 
This study included two components: 50 
1) In vitro control experiment  51 
This experiment aimed to establish the longevity of CT DNA post antibiotic exposure and to assess the ability for 52 
dPCR to detect mRNA only. A single isolate of C. trachomatis genovar D was used to infect McCoy B cells at a 53 
multiplicity of infection (MOI) of 1.0. The infected cells were then treated with 0.250 µg/ml azithromycin (twice 54 
the MIC for this isolate), 4 h post infection and wells harvested at 46 h, 96 h and 144 h into RNAlater™ 55 
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stabilization solution (Thermo Fisher Scientific, Waltham, Massachusetts, USA). Also included was an infected 56 
and un-infected cell line with no azithromycin added, to act as positive and negative controls, respectively. The 57 
RTqPCR crossing threshold was then plotted over the azithromycin treatment in hours post infection and was 58 
then plotted as a line graph using Microsoft Excel 2013. 59 
2) Evaluation of mRNA assay in a cohort of women diagnosed with chlamydia 60 
Specimens from a sample of CT DNA positive women participating in the Australian Chlamydia Treatment Study 61 
(ACTS) were included in this study.  ACTS was a cohort study that aimed to estimate chlamydia treatment failure 62 
in women treated with one gram azithromycin following diagnosis with urogenital CT [1]. To be eligible for 63 
ACTS, women were diagnosed with chlamydia using the Cobas® 4800 CT/NG test (Roche Molecular 64 
Diagnostics) according to the manufacturer’s instructions; women were treated with one gram azithromycin and 65 
followed for up to 56 days, with weekly specimen collection for chlamydia load and genovar detection using real 66 
time PCR [1].  A total of 306 women were recruited and 36 tested chlamydia positive on or after day 28 of follow 67 
up. Specimens were available from 29 of these 36 women for this study and included self-collected vaginal swabs 68 
obtained at the time of recruitment (within the clinic) immediately prior to treatment with one gram azithromycin 69 
(visit 1). Follow up specimens were available from 26 women providing self-collected vaginal swabs obtained 70 
approximately seven days after treatment in the clinic (visit 2).  71 
The vaginal swabs were swirled immediately in RNAlater™ stabilization solution and stored at -80C.  Samples 72 
stored in RNAlater™ stabilization solution were extracted and then half of the eluted total nucleic acid (TNA) 73 
was treated with DNase.  74 
DNA extraction 75 
All samples had 200μl aliquot extracted using the automated system, MagNA Pure 96 (Roche Applied Science, 76 
Germany), according to the manufacturer’s instructions using the MagNA Pure 96 DNA and Viral NA Small 77 
Volume Kit. The TNA was then eluted in a final volume of 100μl in MagNA Pure 96 elution buffer. In addition, 78 
with samples from the clinical study, to assess sample and TNA extraction and sample adequacy, an aliquot was 79 
amplified by real time PCR for the human β-globin gene [13-15] (The McCoy B cells were excluded from this 80 
test). 81 
Chlamydia genovar and bacterial load 82 
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All references to CT genovar and DNA bacterial load had a 5μl aliquot of each TNA sample and control, amplified 83 
by a series of real time PCR assays targeting the ompA gene of CT for determination of chlamydial genovar as 84 
described previously [16].  85 
TNA DNase treatment 86 
For each sample and control, 50μl of eluted TNA was treated with a DNase enzyme to degrade the eluted DNA. 87 
Using Ambion Turbo DNA-freeTM Kit according to the manufacturer’s instructions, 0.1 volume of 10x TURBO 88 
DNase buffer and 1U of TURBO DNase was added to the TNA elution and incubated for 30min at 37°C. 89 
Following this, 0.1 volume of DNase inactivation reagent was added and incubated for 5min at room temperature. 90 
The entire volume was then pelleted by centrifugation at 10, 000 x g for 1.5min and the supernatant collected for 91 
testing.  92 
Messenger ribonucleic acid (mRNA) real time PCR detection 93 
All references to the detection of CT mRNA using the RTqPCR detection method were detected using the 94 
published method [11] with the following modifications. A 3’ spacer (3SpC3) was added to probe CtP1 to stop 95 
extension on CtR1. We used the following enzymes for detection: the Roche reverse transcription enzyme for the 96 
detection of RNA targets and Bioline SensiFAST enzyme for the detection of contaminating DNA targets; both 97 
enzymes were used as per the manufactures instructions.   98 
Messenger ribonucleic acid (mRNA) digital PCR detection 99 
All references to the detection of CT mRNA using the dPCR detection method used an adapted version of the 100 
published RTqPCR method to Bio-Rad’s dPCR system using the advanced onestep reverse transcription enzyme 101 
as per the manufactures instructions. Any samples with ≤3 positive droplets were re-tested in triplicate, if the 102 
sample returned ≥4 positive droplets combined from the triplicate testing then this sample was assessed as 103 
positive. If <4 positive droplets were detected then the sample was called negative as per manufacture protocols.  104 
Statistical analysis 105 
We produced scatter plots, generated lines of best fit using linear regression and calculated Pearson correlation 106 
coefficients between the DNase treated and untreated TNA results for visit 1 and 2 separately. We then examined 107 
the concordances between RTqPCR and dPCR with DNA detection (see below for detail of assays). We calculated 108 
the percentage concordance, the agreement between the two assays using Cohen’s Kappa and the number of 109 
infections that would be detected using the two assays. All analyses undertaken were performed using R 3.2.4. 110 
Ethics approval 111 
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Ethical approval for this study was granted by the Alfred Hospital Ethics Committee (HREC No.  223/12) and the 112 
Southern Eastern Sydney Local Health District Human Research Ethics Committee (Southern Sector) (HREC No. 113 
12/143).  114 
Results 115 
In vitro control experiment  116 
CT infected McCoy cells treated with azithromycin were found to be mRNA negative by 46 h post treatment. 117 
However, DNA was detected up to 6 days post treatment (Figure 1).    118 
Evaluation of mRNA assay in clinical samples of CT positive women 119 
Using dPCR, there was a strong correlation between mRNA and DNA (r=0.9, p<0.01) (Figure 2) in the 29 120 
available specimens at visit 1 (pre-treatment visit). Of these 29, 23 had both mRNA and DNA detected (79.3%). 121 
For 6 specimens at visit 1, only DNA was detected (20.7%;95%CI; 78.0, 39.7) 122 
Of the 23 women who had both mRNA and DNA detected at visit 1, 20 provided samples for visit 2.  There was 123 
poor correlation between mRNA and DNA at visit 2 (7 days post-azithromycin) (r=0.14, p=0.55). Only one had 124 
both mRNA and DNA detected ([12.09%; 95%CI: 10.40, 34.58]; 11 had neither mRNA nor DNA detected and 125 
eight had only DNA detected 42.11% (95%CI: 20.25, 66.50).  126 
Concordance and agreement of mRNA RTqPCR and dPCR with DNA: 127 
Concordance and agreement with DNA assay results were higher for dPCR (Kappa = 48.21% concordance 128 
72.73%) than RTqPCR (Kappa = 37.98%, concordance 65.45%). Overall, an additional four specimens were 129 
detected as CT positive (7.3%) using dPCR compared with negative for qPCR (Table 1). The Cohen’s Kappa for 130 
agreement between qPCR and dPCR was 84.93% (95%CI: 70.87, 98.99) (table 2). The limit of detection for 131 
qPCR and dPCR was established at 2500 and 200 copies of mRNA per swab, respectively. All samples had beta-132 
globin detected using quantitative qPCR. 133 
Discussion 134 
We are the first to have developed a dPCR method to detect CT mRNA in self collected vaginal swabs and have 135 
demonstrated that mRNA becomes non-detectable within seven days following treatment with azithromycin. 136 
Using this assay, we found that approximately 20% of women who tested positive for chlamydia DNA were 137 
negative for chlamydia mRNA at visit 1 raising the question about whether these cases have spontaneously 138 
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resolved between initial diagnosis and treatment or whether the initial test result did not represent a viable 139 
infection.. We also found that if those diagnosed chlamydia DNA positive are re-tested too early following 140 
treatment, over 40% will still have DNA detected but no mRNA and are unlikely to represent viable infection.  141 
Our finding of approximately 20% mRNA negative is similar to those of Janssen and colleagues [17] who 142 
developed a viability PCR (V-PCR) assay to assess CT viability and found that 24% of vaginal swabs from women 143 
diagnosed CT PCR positive had non-viable DNA only.   Unlike our assay which quantified mRNA as a marker 144 
of viable CT, their V-PCR assay consisted of propidium monoazide (PMA) treatment prior to DNA extraction 145 
followed by quantitative PCR targeting the ompA gene for the detection of CT DNA. Both mRNA and V-PCR 146 
methods rely on efficient degradation of non-cellular DNA, this is difficult to control when the following test is 147 
detecting DNA (V-PCR). However, we were able to utilize the differences between DNA and mRNA to asses 148 
this degradation in each sample, resulting in a more reliable detection of actively transcribing organisms.  149 
 150 
When interpreting chlamydia test results, it is important to be mindful of the limitations when detecting DNA 151 
using NAAT. The in vitro study presented here showed that using NAAT targeting mRNA, viable bacteria can 152 
be detected and differentiated from non-viable DNA. We also show that within 46 h post azithromycin treatment, 153 
infected McCoy B cells at an MOI of 1.0 have been completely cleared of viable bacteria, while non-viable CT 154 
DNA is still present for up to six days. A DNA PCR test with a specificity of 99.5% in a population with a 155 
prevalence of about 4%, will lead to about 13% of test results being false positive (positive predictive value of 156 
13%). Being able to differentiate between viable and non-viable infection could minimise unnecessary treatment 157 
and any psychosocial consequences of a positive chlamydia diagnosis. While we don’t advocate using mRNA 158 
tests as an initial screening test, they may be of value as an ancillary test when there may be some concern over 159 
the accuracy of a NAAT test result, particularly in a low prevalence population. 160 
By comparing the concordance of mRNA detection to DNA detection for both the published RTqPCR method 161 
and our modified dPCR method we found that dPCR would detect an additional 7% more cases of chlamydia than 162 
the published RTqPCR method in the detection of CT mRNA. The additional four samples positive for CT mRNA 163 
using dPCR had concentrations ranging between 205 and 2500 copies of mRNA per swab. Interestingly these 164 
four discrepant samples represented four out of the seven lowest concentrations of all detected samples. These 165 
results indicate a limit of detection for RTqPCR and dPCR as 2500 and 200 copies of mRNA per swab 166 




At visit 1 the there was a strong linear relationship between the DNA and mRNA (dPCR method) quantitation 169 
data that was highly significant (p<0.001). At visit 2 the linear relationship was lost suggesting that post antibiotic 170 
treatment there is a rapid and marked decline in detectable mRNA activity, a result which is not evident in the 171 
detection of DNA alone. This confirms earlier studies that have shown that DNA can last for several days to 172 
weeks following treatment and testing too early (within 3 weeks) following treatment with a DNA based test can 173 
lead to incorrect assumptions of treatment failure or re-infection [18].  174 
Possible limitations of this study are that the RNAlater™ stabilization solution samples were collected and stored 175 
for up to 1 year before being tested for mRNA. Although all possible efforts were done to limit the amount of 176 
mRNA degradation we can’t exclude this possibility. We also note that as the samples were self-collected swabs 177 
there could be considerable sampling variability; however previous studies have indicated this is an adequate 178 
collection method [19]. We found all samples had human beta-globin detected using a quantitative PCR 179 
demonstrating adequate sampling was performed. However, we did not perform any mRNA internal controls and 180 
therefore cannot exclude degradation of the mRNA post sample processing. Although, with our results simular 181 
those obtained by Janssen and colleagues, we are confident in our findings.    182 
We conclude that by utilising our adapted dPCR method for the detection of CT mRNA we can accurately detect 183 
and quantify viable CT infections and discriminate this from non-viable DNA to a sensitivity of 200 copies of 184 
mRNA per swab. This study demonstrates that tests are available that can identify molecular markers of viable 185 
chlamydia DNA (specifically intra-cellular bacteria) as a marker of viable infection. Given increasing concerns 186 
about over-use of antibiotics and the potential psychosocial consequences of a positive chlamydia test result, 187 
consideration should be given to further development and use of mRNA tests as ancillary tools to detect viable 188 
chlamydia infections when there is any doubt.  189 
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Figure 1: CT mRNA and DNA qPCR detection 
post 0.250µg/ml azithromycin treatment
mRNA DNA





































Total (%) Concordance Kappa (95% CI) 
Detected Not Detected 
mRNA 
qPCR 
   
 
    





19 16 35 (63.6) (20.28, 55.68) 
Total (%) 39 (70.9) 16 (29.1) 55        
mRNA 
dPCR 
        





































mRNALog ~  0.07 + 0.06 *DNALog
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15 16 31 (56.4) (29.09, 67.33) 
Total (%) 39 (70.9) 16 (29.1) 55         




Table 2. Cohens Kappa for agreement between RTqPCR and dPCR detection 




Total (%) Kappa (95% CI) 
Detected Not Detected 
dPCR        
Detected 20 4 24 (43.64) 84.93% 
Not 
Detected 
0 31 31 (56.36) (70.87, 98.99) 
Total (%) 20 (36.36) 35 (63.64) 55     
* Based on visit 1 and visit 2 data combined (55 samples) 254 
 255 
 256 
